Evaluation of Humoral Immune Responses to Vaccination with Tetanus Toxoid and KLH in Rituximab-Treated Follicular Non-Hodgkin’s Lymphoma Patients Compared to Healthy Volunteers
Abstract:Introduction: Since rituximab is known to rapidly deplete B lymphocytes in the blood for 6–12 months after administration, there has been interest in determining whether this results in a clinically significant impact on humoral responses to common vaccines. Therefore, we designed a trial in patients with lymphoma to study vaccination response to recall and novel antigens and to document any changes in antibody titers to specific common antigens following rituximab treatment. Vaccination of healthy control sub… Show more
“…Six of the 42 studies (14%) described application of KLH challenge to assess the activity of drugs in late‐phase clinical trials and observational studies. Collectively these studies attest to suppression of the humoral immune response to KLH by anti‐CD20 agents (rituximab and ocrelizumab), 48,49 S1PR modulation (fingolimod), 50 IMPDH inhibition (mycophenolic acid), 51 and lack of effect of an anti‐α4‐integrin mAb (natalizumab) 52 . In one observational study of patients who underwent renal transplantation receiving prednisolone and cyclosporine, the use of everolimus as a third agent was associated with retention of primary humoral immune response to KLH, in contrast to complete suppression of response seen with mycophenolic acid as a third agent 53 …”
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
“…Six of the 42 studies (14%) described application of KLH challenge to assess the activity of drugs in late‐phase clinical trials and observational studies. Collectively these studies attest to suppression of the humoral immune response to KLH by anti‐CD20 agents (rituximab and ocrelizumab), 48,49 S1PR modulation (fingolimod), 50 IMPDH inhibition (mycophenolic acid), 51 and lack of effect of an anti‐α4‐integrin mAb (natalizumab) 52 . In one observational study of patients who underwent renal transplantation receiving prednisolone and cyclosporine, the use of everolimus as a third agent was associated with retention of primary humoral immune response to KLH, in contrast to complete suppression of response seen with mycophenolic acid as a third agent 53 …”
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.